Yahoo
Stockholm - Free Realtime Quote SEK

Xvivo Perfusion AB (publ) (XVIVO.ST)

196.30 -3.40 (-1.70%)
As of 4:24:45 PM GMT+1. Market Open.
Chart Range Bar
Loading chart for XVIVO.ST
  • Previous Close 199.70
  • Open 198.80
  • Bid 196.20 x --
  • Ask 196.60 x --
  • Day's Range 192.90 - 199.10
  • 52 Week Range 160.10 - 314.80
  • Volume 29,262
  • Avg. Volume 79,118
  • Market Cap (intraday) 6.183B
  • Beta (5Y Monthly) 1.47
  • PE Ratio (TTM) 48.00
  • EPS (TTM) 4.09
  • Earnings Date Oct 22, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 304.00

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

www.xvivogroup.com

207

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .

YTD Return

XVIVO.ST
5.20%
OMX Stockholm 30 Index (^OMX)
13.95%

1-Year Return

XVIVO.ST
7.56%
OMX Stockholm 30 Index (^OMX)
19.22%

3-Year Return

XVIVO.ST
19.05%
OMX Stockholm 30 Index (^OMX)
54.47%

5-Year Return

XVIVO.ST
40.61%
OMX Stockholm 30 Index (^OMX)
41.74%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 252.56M
Earnings 44.62M
Profit Margin 17.67%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
50M
100M
150M
200M
250M
8.0%
10.0%
12.0%
14.0%
16.0%

Analyst Insights

View More

Analyst Price Targets

260.00
304.00 Average
196.30 Current
360.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.44%

  • Return on Assets (ttm)

    3.22%

  • Return on Equity (ttm)

    5.91%

  • Revenue (ttm)

    958.65M

  • Net Income Avi to Common (ttm)

    128.85M

  • Diluted EPS (ttm)

    4.09

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    313.24M

  • Total Debt/Equity (mrq)

    5.32%

  • Levered Free Cash Flow (ttm)

    2.51M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: